AR072858A1 - Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden - Google Patents

Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden

Info

Publication number
AR072858A1
AR072858A1 ARP090101320A ARP090101320A AR072858A1 AR 072858 A1 AR072858 A1 AR 072858A1 AR P090101320 A ARP090101320 A AR P090101320A AR P090101320 A ARP090101320 A AR P090101320A AR 072858 A1 AR072858 A1 AR 072858A1
Authority
AR
Argentina
Prior art keywords
polymer
compositions
posaconazol
formulations
high density
Prior art date
Application number
ARP090101320A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41199703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072858(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR072858A1 publication Critical patent/AR072858A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP090101320A 2008-04-15 2009-04-15 Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden AR072858A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US16648709P 2009-04-03 2009-04-03

Publications (1)

Publication Number Publication Date
AR072858A1 true AR072858A1 (es) 2010-09-29

Family

ID=41199703

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101320A AR072858A1 (es) 2008-04-15 2009-04-15 Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden

Country Status (19)

Country Link
US (2) US20110123627A1 (https=)
EP (1) EP2285351A2 (https=)
JP (3) JP2011516612A (https=)
KR (1) KR20110004852A (https=)
CN (2) CN104983701A (https=)
AR (1) AR072858A1 (https=)
AU (1) AU2009236289B2 (https=)
BR (1) BRPI0910627A2 (https=)
CA (1) CA2720849A1 (https=)
CL (1) CL2009000902A1 (https=)
CO (1) CO6311066A2 (https=)
MX (1) MX2010011295A (https=)
NZ (1) NZ588460A (https=)
PE (1) PE20091778A1 (https=)
PH (1) PH12015500492A1 (https=)
SG (1) SG10201403986UA (https=)
TW (1) TWI388324B (https=)
WO (1) WO2009129300A2 (https=)
ZA (1) ZA201007370B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
PT2810660T (pt) 2013-06-03 2017-08-16 Shinetsu Chemical Co Composição para extrusão termofusível e método para produzir produto de extrusão termofusível com o uso da mesma
EP2837391B1 (en) * 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104510707A (zh) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 一种泊沙康唑固体分散体及其制备方法
CN104546667A (zh) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 含泊沙康唑的固体分散体及其制备方法
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
CN104971045A (zh) * 2014-04-11 2015-10-14 上海宣泰医药科技有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
US11058682B2 (en) 2015-08-08 2021-07-13 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP3210599B1 (en) 2016-02-26 2024-08-28 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
US20180282527A1 (en) * 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
WO2020159562A1 (en) * 2019-01-29 2020-08-06 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US20230149452A1 (en) * 2020-04-06 2023-05-18 Yogesh BENDALE Structurally defined, better tolerated, orally adminstered, processed arsenolite, a process for its preparation, a pharmaceutical composition and uses thereof
WO2022034232A1 (en) 2020-08-13 2022-02-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant high-strength formulation containing posaconazole
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
US20240390363A1 (en) 2021-11-25 2024-11-28 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Granules containing posaconazole
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
CN114184721A (zh) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 泊沙康唑残留溶剂的检测方法
CN115721601A (zh) * 2022-11-23 2023-03-03 无锡福祈制药有限公司 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
EP1372394A1 (en) * 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability
WO2003077827A1 (en) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
WO2006034080A2 (en) * 2004-09-17 2006-03-30 Nektar Therapeutics Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
JP2009538927A (ja) * 2006-05-30 2009-11-12 エラン ファーマ インターナショナル，リミティド ナノ粒子状のポサコナゾール製剤
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物

Also Published As

Publication number Publication date
AU2009236289B2 (en) 2014-08-21
CA2720849A1 (en) 2009-10-22
AU2009236289A1 (en) 2009-10-22
CN104983701A (zh) 2015-10-21
CO6311066A2 (es) 2011-08-22
WO2009129300A3 (en) 2010-02-11
US20110123627A1 (en) 2011-05-26
SG10201403986UA (en) 2014-10-30
US20150150990A1 (en) 2015-06-04
ZA201007370B (en) 2011-06-29
PE20091778A1 (es) 2009-11-13
JP2016074698A (ja) 2016-05-12
KR20110004852A (ko) 2011-01-14
EP2285351A2 (en) 2011-02-23
MX2010011295A (es) 2010-11-12
TWI388324B (zh) 2013-03-11
JP2014139230A (ja) 2014-07-31
CN102065842A (zh) 2011-05-18
NZ588460A (en) 2012-07-27
PH12015500492A1 (en) 2017-04-10
BRPI0910627A2 (pt) 2015-09-22
WO2009129300A2 (en) 2009-10-22
CL2009000902A1 (es) 2010-07-23
JP2011516612A (ja) 2011-05-26
TW200946121A (en) 2009-11-16

Similar Documents

Publication Publication Date Title
AR072858A1 (es) Composiciones de alta densidad que contienen posaconazol y formulaciones que lo comprenden
BR112012033077A2 (pt) composição farmacêutica para administração intravenosa, método para tratar ou previnir uma infecção, e, kit
WO2008100867A3 (en) Novel inhibitors hepatitis c virus replication
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
AR057422A1 (es) Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
NO20071610L (no) Immunogen sammensetning
ATE455534T1 (de) Verwendung einer hydrophilen matrix mit einem polyacrylsäurederivat, einem celluloseether und einem sprengmittel zur herstellung eines medikaments zur behandlung von erkrankungen der weiblichen genitalorgane
WO2008005511A8 (en) Novel inhibitors of hepatitis c virus replication
BRPI0612655A8 (pt) composição imunogênica, vacina, kit de vacina para a administração seqüencial ou concomitante, processo para a produção da vacina, método de imunização de um hospedeiro humano contra doença causada por infecção de neisseria meningitidis, e, uso da composição imunogênica.
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
MX2022008086A (es) Preparacion y/o formulacion de proteinas reticuladas con polisacaridos.
BR112012014899A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
WO2008059489A3 (en) Radioimaging applications of and novel formulations of teboroxime
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
Zhang et al. Theranostic quercetin nanoparticle for treatment of hepatic fibrosis
WO2005069933A3 (en) Methods of treating an inflammatory-related disease
SV2008003106A (es) Composicion farmaceutica estable que contiene docetaxel y un metodo para fabricarla
BRPI0511327B8 (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
WO2009134616A3 (en) Novel inhibitors of hepatitis c virus replication
CN114341148B (zh) 抗衰老和抗炎前药及其使用方法
MX2023005533A (es) Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.
JP2019509345A5 (https=)
BR0215936A (pt) Inibidores da alfa-glucosidase a partir de uma fonte natural
BRPI0713371A2 (pt) método para a produção de um produto medicamentoso contendo olmesartan medoxomil, e, produto medicamentoso contendo olmesartan medoxomil

Legal Events

Date Code Title Description
FB Suspension of granting procedure